Therapeutic effect of RAS inhibitors on epigenetic changes in life-style related diseases

Research output: Contribution to journalArticle

Abstract

Recently emerging evidence has shown that epigenetic mechanisms are involved in initiation and progression of life-style related diseases, including hypertension. In this article, we reviewed therapeutic effect of renin-angiotensin system (RAS) inhibitors on epigenetic changes in the disease states. We have recently reported that transcription factor Kruppel-like factor 4(KLF4) is expressed in kidney podocytes and modulates podocyte phenotype by gene-selective epigenetic control, and that the effect of RAS inhibitors is mediated by epigenetic modulation through KLF4 in part. It is suggested that the 'memory' or 'legacy' effect of RAS inhibitors previously reported in human studies may be partly due to the epigenetic modulation by these agents, and further studies are necessary for investigation of new therapeutic target.

Original languageEnglish
Pages (from-to)1933-1938
Number of pages6
JournalNihon rinsho. Japanese journal of clinical medicine
Volume73
Issue number11
Publication statusPublished - 2015 Nov 1

Fingerprint

Therapeutic Uses
Renin-Angiotensin System
Epigenomics
Life Style
Podocytes
Transcription Factors
Hypertension
Phenotype
Kidney
Genes
GKLF protein

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{2165001c8da1444085015961a196242c,
title = "Therapeutic effect of RAS inhibitors on epigenetic changes in life-style related diseases",
abstract = "Recently emerging evidence has shown that epigenetic mechanisms are involved in initiation and progression of life-style related diseases, including hypertension. In this article, we reviewed therapeutic effect of renin-angiotensin system (RAS) inhibitors on epigenetic changes in the disease states. We have recently reported that transcription factor Kruppel-like factor 4(KLF4) is expressed in kidney podocytes and modulates podocyte phenotype by gene-selective epigenetic control, and that the effect of RAS inhibitors is mediated by epigenetic modulation through KLF4 in part. It is suggested that the 'memory' or 'legacy' effect of RAS inhibitors previously reported in human studies may be partly due to the epigenetic modulation by these agents, and further studies are necessary for investigation of new therapeutic target.",
author = "Kaori Hayashi and Hiroshi Itoh",
year = "2015",
month = "11",
day = "1",
language = "English",
volume = "73",
pages = "1933--1938",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "11",

}

TY - JOUR

T1 - Therapeutic effect of RAS inhibitors on epigenetic changes in life-style related diseases

AU - Hayashi, Kaori

AU - Itoh, Hiroshi

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Recently emerging evidence has shown that epigenetic mechanisms are involved in initiation and progression of life-style related diseases, including hypertension. In this article, we reviewed therapeutic effect of renin-angiotensin system (RAS) inhibitors on epigenetic changes in the disease states. We have recently reported that transcription factor Kruppel-like factor 4(KLF4) is expressed in kidney podocytes and modulates podocyte phenotype by gene-selective epigenetic control, and that the effect of RAS inhibitors is mediated by epigenetic modulation through KLF4 in part. It is suggested that the 'memory' or 'legacy' effect of RAS inhibitors previously reported in human studies may be partly due to the epigenetic modulation by these agents, and further studies are necessary for investigation of new therapeutic target.

AB - Recently emerging evidence has shown that epigenetic mechanisms are involved in initiation and progression of life-style related diseases, including hypertension. In this article, we reviewed therapeutic effect of renin-angiotensin system (RAS) inhibitors on epigenetic changes in the disease states. We have recently reported that transcription factor Kruppel-like factor 4(KLF4) is expressed in kidney podocytes and modulates podocyte phenotype by gene-selective epigenetic control, and that the effect of RAS inhibitors is mediated by epigenetic modulation through KLF4 in part. It is suggested that the 'memory' or 'legacy' effect of RAS inhibitors previously reported in human studies may be partly due to the epigenetic modulation by these agents, and further studies are necessary for investigation of new therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=84986601792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986601792&partnerID=8YFLogxK

M3 - Article

C2 - 26619671

AN - SCOPUS:84986601792

VL - 73

SP - 1933

EP - 1938

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 11

ER -